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9q31 is responsible. Although cardiac mvolvament is common and develops with age in 
patients with Duchenne and Becker-type muscular dystrophy caused by dystrophin gene 
mutation, little is known about cardiac involvement in patients with FCMD. This study 
evaluated if cardiac involvement exists in pabents with FCMD. Methods: We evaluated 
left ventricular (LV) function using M-mode and Doppler echocardiography in 35 pabents 
with FCMD. The age ranged from 6 months to 31 years (mean: 11 yrs). A total of 53 
recordings were analysed. LV systolic function parameters included end-diastolic dimen- 
sion, shortening fraction, septal and posterior wall thickness, and mean velocity of cir- 
cumferencial fiber shortening (mVcf) and end-systolic wall stress (ESWS) relationshlp. 
Parameters of LV diastolic function included peak early and late inflow velocity (E and A, 
respectively) and EIA ratio. Results: LV end-diastolic dimension increased to more than 
2SD from normal value in 3 patients (9%). LV shortening fraction decreased to less than 
0.25 and mVcf-ESWS relationship showed decreased mVcf in 9 patients (26%). Df 11 
patients z-15 years of age, 8 patients (73%) showed decreased LV systolic function. Sig- 
nificant correlation between age and LV shortening fraction was observed; LV shortening 
fraction decreased with age. Two patients died of heart failure at 16 and 17 years of age, 
respectively, and histology confirmed the presence of myocardial fibrosis. E/A ratio was 
ratio was < 1 in 31% of patients. No patients showed increased LV wall thickness or con- 
duction abnormality on ECG. Conclusion: LV systolic and diastolic dysfunction are com- 
mon in FCMD and become evident in older children > 15 years of age. 
1062-87 Prevalence and Prognostic Implications of Pulmonary 
Hypertension in Patients With Surgically Proven 
Constrictive Pericarditis 
Deepak R. Talreia, Jae K. Oh, Lieng H. Ling, Hartzell V. Schaff, Mayo Clinic, Rochester, 
MN 
Background: Normal pulmonary artery systolic pressure (PASP) has traditionally been 
used to distinguish constrictive pericarditis (CP) from restrictive myocardial diseases 
@MD), but this criterion has poor specificity. TO better understand the prevalence and 
prognostic implications of pulmonary hypertension in CP, we reviewed a consecutive 
series of patients with proven constriction. 
Methods: Case histories of all patients with the diagnosis of CP confirmed at surgery or 
autopsy at the Mayo Clinic from January 1985 through June 1997 (n=224) ware 
reviewed. Among these patients, 161 had PASP determined by echocardiography and/or 
cardiac catheterization. Thirty-two patients with conflicting data by both techniques were 
excluded. The remaining patients were divided into two groups: group 1 had PASP<BO 
mmHg (n=l03), and group 2 had elevated PASPx50 mmHg (n=26). 
Results: Pulmonary hypertension (PASP>=50 mmHg) was seen in 20%. Among group 2 
patients, mean PASP by echo was 58 mmHg (range, 50.85) and by cardiac catheteriza- 
tion, 59 mmHg (range, 50-85). Comparison of etiologies between groups showed that 
prior cardiovascular surgery (18% vs 38%) and irradiation (13% vs 19%) were more com- 
mon in group 2, while idiopathic (likely viral) etiology was more common in group 1 (29% 
YS 15%). Comparing the patients in group 1 with those in group 2, there was no differ- 
ence in LVEF (56% vs 58%). or frequency of significant MR (2% vs 0%) or TR (5% vs 
4%). Perioperative (30 day) mortality was significantly higher in group 2 (19% vs. 5%). Of 
the late survivors in whom functional class could be determined at 12 to 60 months, func- 
tional status had improved in both groups as determined by statistical matched-pairs t- 
testmg; group 1 NYHA class improved from 2.8 to 1.5 (peO.0001) and in group 2 from 3.4 
to 2.7 (p-zO.04). Furthermore, after pericardiectomy, PASP decreased significantly in 
group 2 patients (average PASP of 61 mmHg preoperatively vs. 46 mmHg postopera- 
tively, pcO.004). 
Conclusion: PASP is elevated in 20 % of patients with surgically proven CP. Patients with 
elevated PASP have higher perioperative mortality, but those who survive pericardiec- 
tomy show clinical improvement as do their counterparts with normal PASP. 
ABSTRACTS - Cardiac Function and Heart Failure 161 A 
dlcts prognosis. OVI can be measured rapidly and inexpensively I” large numbers of 
patients. 
1062-88 A Novel Periodic Breathing Index in Awake Patients 
With Heart Failure Predicts Prognosis 
Robert L. Bard, John M. Nick@ University of Michigan, Ann Arbor, Ml 
Background: The presence of periodic breathing (PB) in awake patients has not been 
clearly established. We hypothesized that PB could be assessed with a quantitative 
mdex that would predict patient prognosis in awake heart failure (HF) patients. 
Methods: We assessed PB in 422 HF patients. Resting gas exchange was measured 
after 1 mm of rest in Fowler’s position. PB was quantified by the oscillatory ventilation 
index (OVI), defined as the maximal sequential difference between peak and nadir venti- 
lation divided by the average ventilation durmg 1 min. Patients were followed for up to 5 
yrs, average 2.6 yrs. OVI was compared to other potential covariate predictors of survival 
including age, gender, e]ection fraction (EF), blood pressure, heart rate, serum sodium, 
QRS prolongation, etiology, and peak oxygen consumption (peak V02). 
Results: Forty-four patients had severe PB defined as an OVI > 30%. These patients 
ware matched to 44 comparison controls without PB according to peak VQ. age, gen- 
der, and ebology. PB patients had greater mortality rates than controls by Kaplan-Meier 
survival analysis, p=O.O04. Usmg a Cox regression model for all 88 patients, only the 
covariates OVI, EF, and serum sodium predicted survival. OVI quartile also predicted 
mortality (p= 0.002) with a relatwe mortality risk of 1.9 par quartile increment. 
Conclusion: The OVI. a novel mdex of PB in awake patients wth HF, accurately pra- 
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1085-70 la There Risk Associated With the Use of Nesiritide for 
Acute Heart Failure? 
Jonathan Sackner-Bernstein Marcin Kowalski, Marshal Fox, St. Luke&Roosevelt 
Hospital Center, New York, NY 
Background Nesiritide (NES) improves symptoms in patients with acutely decompen- 
sated heart failure compared to placebo. Although safer than dobutamine, its risk relative 
to diuretic and vasodilator drug (DVD) therapy is unclear. We repolt the 30 day (30d) and 
6 month (6m) risks of death with NES compared to DVD. Methods Two trials were iden- 
tified comparing NES to DVD, VMAC and Proaction, and survival rates were obtained 
from the FDA website and from presentations to investor conferences. Odds ratio (OR) 
using random effects model was calculated for m&.-analysis of risk of death within 306 
using Mantel-Haenszel test applied to data from these 2 studies. 6m risk was determined 
from Kaplan-M&r analysis using intention-to-treat principle and grouping pabents by the 
3 randomized treatment groups (neither of which were done m VMAC analysis) using a 
Pet0 and Pet& generalized Wilcoxon test. Results. 735 patients were included in the 
analysis of 30d risk and 498 in that for 6m risk. NES trended towards higher risk by 30d 
(crude mortality 7.2% vs. 3.6% OR = 1.97, 95% Cl of 0.98-3.95, p= 0.057). At 6m, by 
intent to treat analysis NES trended toward higher risk of death (p = 0.068, crude mortal- 
ity rates of 33%, 22%, and 20% for NES adjustable dose, NES fixed dose and nitroglyc- 
erin (DVD) respectively. 
Kaplan-Meier analysis comparing NES adjustable dose, NES fixed dose and all NES 
treated patients to DVD at 6m revealed OR of 1.97 (1.06-3.67), 1.12 (0.71-1.78) and 1.27 
(0.83-1.96), log rank p=O.OlE. 0.49, and 0.17, respectively. Conclusions. Compared to 
DVD, NES appears to be a higher risk treatment for acutely decompensated heart failure. 
Although effective at reducing symptoms compared to placebo, the modest acute clinical 
benefit compared to DVD (when including IV nitroglycerin) coupled with possible long- 
term risk need to be considered prior to widespread cllnical use. A prospective mortality 
trial is necessary. Analysis of public domain information available from the FDA and from 
the investment community can provide added insight about the risk:benefit ratio of medi- 
cal treatments. 
1085-71 Effect of Nesiritide on Length of Hospital Stay in 
Decompensated Heart Failure 
Richard Chanq, Wafaa A. Elatre, J. Thomas Heywood, Loma Linda Unwersity. Loma 
Linda, CA 
Background: Nesiritide (Nes) has been shown to rapidly improve hemodynamics and 
decrease symptoms in patients with heart failure (HF) when added to cOnventional ther- 
apy. However Nes is more expensive than diuretics; it is unclear if accelerated symptom- 
atic improvement translates mto reduced length of stay (LOS) without compromising 
renal function. 
Objective: To determine the effect of Nes on LOS and renal function. Methods: Demo- 
araphics. concurrent medications and lab values were retrospectivelv evaluated for 130 _ , 
consecutwe patients discharged from the Coronary Care Unit with a diagnow of HF from 
Julv 2001 -Julv 2002. Analvsis: Univariate analvses were done to compare 58 Patients 
(Nds Group) who intially received Nes for a ma& duration of 2.2 days {median 1.7) with 
72 patients who did not (NON Nes Group). Results: The Nes group had a lower baseline 
EF. SP, higher creatinine and longer QRS (see Table). Despite these parameters indicat- 
ing that the Nes patients were more III, the LOS in the NES group was significantly 
shorter compared to the non-NES group (p=O.O02). Multiple linear regression analysis 
Indicated that LOS was significantly related to NES usage (p=O.OOl). 
